Dronedarone Hydrochloride is a pharmaceutical active pharmaceutical ingredient (API) belonging to the antiarrhythmic drug class. It is a multichannel ion-channel blocker used in pharmaceutical formulations for the management of selected atrial arrhythmias.
Dronedarone Hydrochloride is the hydrochloride salt of dronedarone, a benzofuran derivative with antiarrhythmic properties. It affects several cardiac ion channels and helps regulate abnormal electrical activity in the heart.
Dronedarone Hydrochloride is a synthetic small-molecule API used in the manufacture of pharmaceutical formulations. It is primarily associated with oral antiarrhythmic formulations for appropriately selected patients with atrial fibrillation or atrial flutter.
Dronedarone exhibits activity across multiple ion-channel pathways. Its pharmacological effects include potassium-channel blockade, sodium-channel blockade, calcium-channel blockade and antiadrenergic activity. These combined effects influence cardiac conduction and repolarization and help maintain normal cardiac rhythm.
Dronedarone Hydrochloride is used in pharmaceutical formulations for:
Its use is subject to approved indications, contraindications and regulatory labeling.
Dronedarone Hydrochloride is generally described as a white to off-white crystalline powder. It has limited water solubility and is suitable for pharmaceutical formulation applications under appropriate handling and storage conditions.
Dronedarone Hydrochloride API intended for pharmaceutical manufacturing should be produced under appropriate GMP controls and tested against applicable quality requirements. Analytical evaluation may include identification, assay, related substances, water content, residual solvents, elemental impurities and other relevant quality attributes.
Dronedarone Hydrochloride is a specialized cardiovascular API used in the development and manufacture of antiarrhythmic pharmaceutical formulations. Pharmaceutical manufacturers and formulation developers can evaluate the API based on applicable pharmacopoeial and regulatory requirements, analytical documentation and batch-specific Certificate of Analysis.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | Approximately 140°C – 145°C |